The Mulligan Lab is currently completing treatments of the SOD1G93A mouse model of ALS with four different doses of the Hsp70 protein and hopes to have the dose response study complete by the end of March/mid-April. With positive results (hopefully), our ALS scientists and clinicians will begin to design initial clinical trials in patients.
This Holiday Season (or anytime of year) if you shop Amazon, then the AmazonSmile Foundation will donate 0.5% of the purchase price from your eligible purchases. Click Blazeman Foundation for ALS for a direct link.
An update on the Hsp70 research being conducted in the Milligan lab and how your donations are contributing to the future success in the WarOnALS.
Blazeman postdoctural fellow, Dr. Mugdha Deshpande working with others in the lab of Dr. Rodal at Brandeis University found and fixed an abnormality in flies’ nervous system, restoring their ability to crawl. Understanding what goes wrong inside nerve cells could have implications for human disease.
The Blazeman Foundation for ALS support at Brandeis is critical to the efforts of ALS research and to training the next generation of ALS researchers.
Update on the third year of research supported by the Blazeman Foundation for ALS to the Rodal Lab that resulted in a primary research article (currently under peer review), as well as a published review article.
The Rodal lab submitted their first paper describing the Blazeman-funded work a few months ago (to the Journal of Neuroscience), and the peer reviewers were very positive about it. The reviewers asked the lab to do a few more experiments before it can be accepted, and they’re working very hard on completing those. In the meantime, they are also working very hard on a second paper that incorporates work from mammalian neurons. Drs. Deshpande and Rodal were also invited to write a review article summarizing the current status of the field, and how studying transport in neurons has led to increased understanding of neurological disease.
The Milligan lab wishes to thank the Blazeman Foundation and all ALS Warriors for continued support of their work. While this progress report focuses on our recombinant Hsp70 protein as a potential therapeutic for ALS, they have included pictures of the members of the lab and the projects on which they focus their efforts.